CN100546581C - 用于治疗神经病学病症的包含抗癫痫药的组合 - Google Patents

用于治疗神经病学病症的包含抗癫痫药的组合 Download PDF

Info

Publication number
CN100546581C
CN100546581C CNB2004800092188A CN200480009218A CN100546581C CN 100546581 C CN100546581 C CN 100546581C CN B2004800092188 A CNB2004800092188 A CN B2004800092188A CN 200480009218 A CN200480009218 A CN 200480009218A CN 100546581 C CN100546581 C CN 100546581C
Authority
CN
China
Prior art keywords
administered
combination product
epilepsy
alkylidene
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800092188A
Other languages
English (en)
Chinese (zh)
Other versions
CN1767832A (zh
Inventor
D·艾特肯
K·林根霍尔
M·施穆茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1767832A publication Critical patent/CN1767832A/zh
Application granted granted Critical
Publication of CN100546581C publication Critical patent/CN100546581C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
CNB2004800092188A 2003-04-04 2004-04-02 用于治疗神经病学病症的包含抗癫痫药的组合 Expired - Fee Related CN100546581C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0307860.7A GB0307860D0 (en) 2003-04-04 2003-04-04 Organic compounds
GB0307860.7 2003-04-04

Publications (2)

Publication Number Publication Date
CN1767832A CN1767832A (zh) 2006-05-03
CN100546581C true CN100546581C (zh) 2009-10-07

Family

ID=9956223

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800092188A Expired - Fee Related CN100546581C (zh) 2003-04-04 2004-04-02 用于治疗神经病学病症的包含抗癫痫药的组合

Country Status (10)

Country Link
US (1) US20060194766A1 (enExample)
EP (1) EP1620103A1 (enExample)
JP (1) JP2006522062A (enExample)
CN (1) CN100546581C (enExample)
AU (1) AU2004226825B2 (enExample)
BR (1) BRPI0409170A (enExample)
CA (1) CA2521274A1 (enExample)
GB (1) GB0307860D0 (enExample)
MX (1) MXPA05010707A (enExample)
WO (1) WO2004087161A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
EP2164489A2 (en) * 2007-07-13 2010-03-24 Eisai R&D Management Co., Ltd. Combination of ampa receptor antagonists and acetylcholinesterase inhibitors for the treatment of neuropathic pain
WO2009015244A1 (en) * 2007-07-23 2009-01-29 Synosia Therapeutics Rufinamide for the treatment of post-traumatic stress disorder
PL3061821T3 (pl) 2009-07-22 2020-01-31 PureTech Health LLC Kompozycje do leczenia zaburzeń łagodzonych przez aktywację receptora muskarynowego
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
CN112789042A (zh) 2018-09-28 2021-05-11 卡鲁娜治疗学有限公司 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB864536A (en) * 1957-11-06 1961-04-06 Sapos S A Lab ª‡-ethyl-phenylacetylurea
US3489836A (en) * 1964-01-06 1970-01-13 Ici Ltd 5-amino - 10,11-dihydro - 5h - dibenzo (a,d)-cycloheptenes and derivatives in pharmaceutical compositions and the use thereof for the treatment of epilepsy
WO1989005642A1 (en) * 1987-12-22 1989-06-29 Ferkany John W Dextrorphan potentiator for anticonvulsant composition and method
US5095033A (en) * 1991-03-01 1992-03-10 Laboratoires Biocodex Method for treating epilepsy
EP0637449A1 (en) * 1993-07-06 1995-02-08 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Use of L-carnitine or acyl L-carnitines and valproate for treating seizure disorders
CN1234037A (zh) * 1996-10-24 1999-11-03 诺瓦提斯公司 取代的氨基链烷膦酸
CN1265889A (zh) * 1999-03-06 2000-09-13 王学勇 一种治疗癫痫病的药物
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
CN1402637A (zh) * 1999-12-01 2003-03-12 Ucb公司 用于治疗cns疾病的吡咯烷乙酰胺衍生物或者其组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017692A1 (en) * 1996-10-19 1998-04-30 University Of Wales, Bangor Preparation of chemically reactive polysaccharides
US6306909B1 (en) * 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
KR20050044396A (ko) * 2001-11-12 2005-05-12 노파르티스 아게 정동 및 주의력 장애 및 신경병성 통증 치료용 의약제조에 사용하기 위한 모노히드록시카르바마제핀

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB864536A (en) * 1957-11-06 1961-04-06 Sapos S A Lab ª‡-ethyl-phenylacetylurea
US3489836A (en) * 1964-01-06 1970-01-13 Ici Ltd 5-amino - 10,11-dihydro - 5h - dibenzo (a,d)-cycloheptenes and derivatives in pharmaceutical compositions and the use thereof for the treatment of epilepsy
WO1989005642A1 (en) * 1987-12-22 1989-06-29 Ferkany John W Dextrorphan potentiator for anticonvulsant composition and method
US5095033A (en) * 1991-03-01 1992-03-10 Laboratoires Biocodex Method for treating epilepsy
EP0637449A1 (en) * 1993-07-06 1995-02-08 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Use of L-carnitine or acyl L-carnitines and valproate for treating seizure disorders
CN1234037A (zh) * 1996-10-24 1999-11-03 诺瓦提斯公司 取代的氨基链烷膦酸
CN1265889A (zh) * 1999-03-06 2000-09-13 王学勇 一种治疗癫痫病的药物
CN1402637A (zh) * 1999-12-01 2003-03-12 Ucb公司 用于治疗cns疾病的吡咯烷乙酰胺衍生物或者其组合物
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LY 300164, a novel antagonist of AMPA/kainate receptors,potentiates the anticonvulsive activity of antiepileptic drugs. Stanislaw J. CZUCZWAR.EUROPEAN JOURNAL OF PHARMACOLOGY,Vol.359. 1998 *

Also Published As

Publication number Publication date
AU2004226825B2 (en) 2007-08-16
BRPI0409170A (pt) 2006-04-11
MXPA05010707A (es) 2005-12-12
WO2004087161A1 (en) 2004-10-14
CA2521274A1 (en) 2004-10-14
JP2006522062A (ja) 2006-09-28
GB0307860D0 (en) 2003-05-14
AU2004226825A1 (en) 2004-10-14
EP1620103A1 (en) 2006-02-01
US20060194766A1 (en) 2006-08-31
CN1767832A (zh) 2006-05-03

Similar Documents

Publication Publication Date Title
JP2003507421A (ja) トラマドール物質及び抗痙攣薬を含んで成る組成物
JP2007262096A (ja) 痙攣または発作を処置または予防するための組成物および方法
JP2012025756A (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
HU202108B (en) Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol
JP2007517901A (ja) 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物
HUE033180T2 (en) Peptide compounds for the treatment of difficult to cure epileptic diseases
KR101390144B1 (ko) 염증성 장질환 치료제
US8222241B2 (en) Use of dimiracetam in the treatment of chronic pain
US20090312290A1 (en) Combination of a nitrogen mustard analogue and imatinib for treatment of chronic lymphocytic leukemia
CN100546581C (zh) 用于治疗神经病学病症的包含抗癫痫药的组合
JP2009539996A (ja) 腎機能障害を持つ個体における利尿改善方法
NZ543109A (en) Method of improved diuresis in individuals with impaired renal function
JP4739760B2 (ja) バルビツール酸誘導体を使用する運動障害の治療方法
AU2004290890B2 (en) Combinations comprising AMPA receptor antagonists for the treatment of schizophrenia
NL8002041A (nl) Werkwijze voor het bereiden van een analgetisch en myotonolytisch geneesmiddel.
CA2568436A1 (en) Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor
CA2645260A1 (en) Renin inhibitors for the treatment of hypertension
WO2005049042A1 (en) Combinations comprising ampa receptor antagonists for the treatment of tinnitus
WO2005049041A1 (en) Combinations comprising ampa receptor antagonists for the treatment of anxiety disorders
WO2005049039A1 (en) Combinations comprising ampa receptors antagonists for the treatment of affective and attention deficit disorders
WO2005039593A1 (en) Combinations comprising ampa receptor antagonists for the treatment of neuropathic pain
HK1187244A (en) Use of dimiracetam in the treatment of chronic pain

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20091007

Termination date: 20110402